This Article Full Text Full Text (PDF) All Versions of this Article: 105/16/1970    most recent 01.CIR.0000014612.88433.62v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rukshin, V. Articles by Kaul, S. Search for Related Content PubMed PubMed Citation Articles by Rukshin, V. Articles by Kaul, S. Related Collections Platelet function inhibitors Catheter-based coronary interventions: stents

(Circulation. 2002;105:1970.)
© 2002 American Heart Association, Inc.

Basic Science Reports

Comparative Antithrombotic Effects of Magnesium Sulfate and the Platelet Glycoprotein IIb/IIIa Inhibitors Tirofiban and Eptifibatide in a Canine Model of Stent Thrombosis

Vladimir Rukshin, MD; Prediman K. Shah, MD; Bojan Cercek, MD; Ariel Finkelstein, MD; Vivian Tsang, BS; Sanjay Kaul, MD

From the Vascular Physiology and Thrombosis Research Laboratory of the Atherosclerosis Research Center, Cedars-Sinai Burns and Allen Research Institute; Division of Cardiology, Department of Medicine, Cedars-Sinai Medical Center; and University of California at Los Angeles School of Medicine, Los Angeles, Calif.

Correspondence to Sanjay Kaul, MD, Division of Cardiology, Room 5314, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA 90048. E-mail kaul{at}cshs.org

Background— Antithrombotic effects of glycoprotein IIb/IIIa inhibitors and magnesium are known, but their comparative effects on stent thrombosis are not known. Our objective was to compare the antithrombotic effects of the glycoprotein IIb/IIIa inhibitors tirofiban and eptifibatide with magnesium in an ex vivo canine arteriovenous shunt model of stent thrombosis.

Methods and Results— Control nitinol stents were expanded to 2 mm in diameter in a tubular perfusion chamber interposed in the shunt and exposed to flowing arterial blood at a shear rate of 2100 s^-1 for 20 minutes (n=398 perfusion runs in 24 experiments in 8 dogs). The animals were treated intravenously with MgSO₄ (2 g bolusx20 minutes followed by 2 g/h infusion), eptifibatide (double bolus of 180 µg/kg 10 minutes apart followed by 2 µg/kg per minute), or tirofiban (0.3 µg/kg per minute), with or without heparin (50 U/kg). Effects of the test agents on thrombus weight, platelet aggregation (PA), platelet CD62 expression, bleeding time (BT), heart rate, and mean arterial blood pressure were assessed. Treatment with Mg+heparin reduced stent thrombus weight by 78±10% compared with baseline (19±4 mg, P<0.001). The antithrombotic effect of Mg+heparin was equivalent to that observed with tirofiban+heparin (78±13%) and eptifibatide+heparin (84±11%). Magnesium had no significant effect on PA and BT. Tirofiban and eptifibatide inhibited PA by >90% and prolonged BT up to 20 minutes. None of the test agents had effects on CD62 expression or activated clotting time. There were no significant bleeding or hemodynamic complications.

Conclusion— Magnesium produced a significant reduction in acute stent thrombus formation that was equivalent in magnitude to that produced by clinically relevant doses of tirofiban and eptifibatide. Its potential use in percutaneous coronary intervention requires further study.

Key Words: platelets • thrombosis • stents

This article has been cited by other articles:

				T. G. Ruttmann, L. F. Montoya-Pelaez, and M. F. M. James The Coagulation Changes Induced by Rapid In Vivo Crystalloid Infusion Are Attenuated When Magnesium Is Kept at the Upper Limit of Normal Anesth. Analg., June 1, 2007; 104(6): 1475 - 1480. [Abstract] [Full Text] [PDF]

				A. Wadhwa, P. Sengupta, J. Durrani, O. Akca, R. Lenhardt, D. I. Sessler, and A. G. Doufas Magnesium sulphate only slightly reduces the shivering threshold in humans Br. J. Anaesth., June 1, 2005; 94(6): 756 - 762. [Abstract] [Full Text] [PDF]

				G. M. Tong and R. K. Rude Magnesium Deficiency in Critical Illness J Intensive Care Med, January 1, 2005; 20(1): 3 - 17. [Abstract] [PDF]

				V. Rukshin, R. Santos, M. Gheorghiu, P. K. Shah, S. Kar, S. Padmanabhan, B. Azarbal, V. T. Tsang, R. Makkar, B. Samuels, et al. A Prospective, Nonrandomized, Open-Labeled Pilot Study Investigating the Use of Magnesium in Patients Undergoing Nonacute Percutaneous Coronary Intervention with Stent Implantation Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2003; 8(3): 193 - 200. [Abstract] [PDF]